BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系

The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors

近年来,免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)的问世彻底改变了多种恶性肿瘤的治疗格局。但是并非所有患者都能从免疫治疗中获益,免疫治疗的总体有效率偏低。因此,如何筛选免疫治疗获益人群就成为目前关注的热点问题。由于肿瘤的异质性、微环境复杂性、标本可及性等因素,目前用于指导肿瘤免疫治疗的生物标记物存在一定局限性。有研究探索了临床特征对免疫检查点抑制剂疗效的预测作用,其中包括体重指数(Body mass index,BMI)。本文就BMI与恶性肿瘤免疫治疗疗效的关系进行综述。

In recent years,immune checkpoint inhibitors(ICIs)have completely changed the treatment pattern of a variety of malignant tumors.However,not all patients can benefit from immunotherapy,and the overall effective rate is low.Therefore,how to screen the people who benefit from immunotherapy is currently a hot issue.Due to tumor heterogeneity,microenvironment complexity,specimen accessibility and other factors,the current biomarkers used to guide tumor immunotherapy have certain limitations.Studies have explored the predictive effect of clinical features on the efficacy of ICIs,including body mass index(BMI).This article reviews the relationship between BMI and the efficacy of immunotherapy for malignant tumors.